↓ Skip to main content

Randomized Multicenter Phase II Study of Larotaxel (XRP9881) in Combination with Cisplatin or Gemcitabine as First-Line Chemotherapy in Nonirradiable Stage IIIB or Stage IV Non-small Cell Lung Cancer

Overview of attention for article published in Journal of Thoracic Oncology, August 2008
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (63rd percentile)
  • Good Attention Score compared to outputs of the same age and source (67th percentile)

Mentioned by

patent
1 patent

Citations

dimensions_citation
19 Dimensions

Readers on

mendeley
23 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Randomized Multicenter Phase II Study of Larotaxel (XRP9881) in Combination with Cisplatin or Gemcitabine as First-Line Chemotherapy in Nonirradiable Stage IIIB or Stage IV Non-small Cell Lung Cancer
Published in
Journal of Thoracic Oncology, August 2008
DOI 10.1097/jto.0b013e31817e6669
Pubmed ID
Authors

Petr Zatloukal, Radj Gervais, Johan Vansteenkiste, Léon Bosquee, Christiana Sessa, Etienne Brain, Eric Dansin, Thierry Urban, Nadine Dohollou, Michèle Besenval, Elisabeth Quoix

Mendeley readers

The data shown below were compiled from readership statistics for 23 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 23 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 5 22%
Student > Bachelor 4 17%
Student > Doctoral Student 3 13%
Student > Ph. D. Student 3 13%
Professor > Associate Professor 2 9%
Other 4 17%
Unknown 2 9%
Readers by discipline Count As %
Medicine and Dentistry 9 39%
Agricultural and Biological Sciences 5 22%
Pharmacology, Toxicology and Pharmaceutical Science 2 9%
Nursing and Health Professions 2 9%
Psychology 1 4%
Other 1 4%
Unknown 3 13%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 January 2015.
All research outputs
#3,548,592
of 12,345,780 outputs
Outputs from Journal of Thoracic Oncology
#600
of 2,344 outputs
Outputs of similar age
#94,388
of 270,526 outputs
Outputs of similar age from Journal of Thoracic Oncology
#9
of 28 outputs
Altmetric has tracked 12,345,780 research outputs across all sources so far. This one is in the 49th percentile – i.e., 49% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,344 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one has gotten more attention than average, scoring higher than 66% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 270,526 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.
We're also able to compare this research output to 28 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.